All In Biotech

Drug Trial Radar · NCT01466153

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

Last checked: Nov 20, 2026Latest source record: May 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

Feb 7, 2012

Primary completion

Jan 8, 2016

Study completion Jan 8, 2016

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Interventions

  • RituximabDrug

    Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles

  • BendamustineDrug

    Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.

  • MEDI-551Drug

    MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

Locations

54 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Burbank, California

  • Research Site

    La Jolla, California

  • Research Site

    Palm Springs, California

  • Research Site

    Skokie, Illinois

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Fargo, North Dakota

  • Research Site

    Dayton, Ohio

  • Research Site

    Newark, Ohio

  • Research Site

    Watertown, South Dakota

  • Research Site

    Lubbock, Texas

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Antwerp, Belgium

  • Research Site

    Arlon, Belgium

  • Research Site

    Kortrijk, Belgium

  • Research Site

    Mons, Belgium

  • Research Site

    Wilrijk, Belgium

  • Research Site

    Yvoir, Belgium

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Amiens, France

  • Research Site

    Bayonne, France

  • Research Site

    Bordeaux, France

  • Research Site

    Le Mans, France

  • Research Site

    Libourne, France

  • Research Site

    Marseille, France

  • Research Site

    Nîmes, France

  • Research Site

    Dortmund, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Freiburg im Breisgau, Germany

  • Research Site

    München, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Haifa, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Bari, Italy

  • Research Site

    Lecce, Italy

  • Research Site

    Meldola, Italy

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.